Cullinan Therapeutics, Inc. SEC filings CGEM

Cullinan Therapeutics, Inc. has 466 filings in SEC EDGAR's recent list, going back to Nov 2, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Apr 28, 2026 Dec 31, 2025
10-K Annual report Mar 10, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 25, 2025 Dec 31, 2024
10-K Annual report Feb 27, 2025 Dec 31, 2024
ARS Annual report to shareholders May 16, 2024 Dec 31, 2023
10-K Annual report Mar 14, 2024 Dec 31, 2023
10-K Annual report Mar 9, 2023 Dec 31, 2022
10-K Annual report Mar 17, 2022 Dec 31, 2021
10-K Annual report Mar 30, 2021 Dec 31, 2020

Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
CGEM (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1789972
Former names
Cullinan Oncology, Inc. (until Apr 2, 2024); Cullinan Management, Inc. (until Feb 22, 2021); Cullinan Oncology, LLC (until Jan 6, 2021)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.